Get the Stockscreener App
2.05
4.65%
-0.10
After Hours:
2.05
Nkarta Inc stock is traded at $2.05, with a volume of 1.97M.
It is down -4.65% in the last 24 hours and down -15.98% over the past month.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$2.15
Open:
$2.18
24h Volume:
1.97M
Relative Volume:
1.33
Market Cap:
$144.67M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.8542
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-7.24%
1M Performance:
-15.98%
6M Performance:
-61.90%
1Y Performance:
-78.49%
1-Day Range:
$2.025
$2.21
1-Week Range:
$2.025
$2.35
52-Week Range:
$1.96
$16.24
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.05 | 144.67M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus.com
What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register
Nkarta's chief medical officer sells $19,003 in stock - MSN
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Nkarta executive sells shares worth $12,843 - MSN
Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com Australia
Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India
Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia
Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat
JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa
Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa
Nkarta's chief technical officer sells $16,383 in stock - MSN
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Geode Capital Management LLC Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Franklin Resources Inc. Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc.: Trying To Find Space In A Crowded Place - Seeking Alpha
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Barclays PLC - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
State Street Corp Purchases 15,569 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):